Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Medifast, Inc.
MED
NYSE·Consumer Cyclical·Personal Products & Services·Mkt cap $122.6M
$10.96
▼ -0.63%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$9.22 - $15.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 24.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary OPTAVIA program combining products with personalized coaching for customer retention
- Established brand recognition and 40+ year track record in weight management industry
- Vertically integrated manufacturing and direct distribution model reducing intermediaries
- Coach-based network creating community engagement and recurring revenue streams
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Revenue decline expected
Rising obesity rates and consumer demand for structured weight management solutions
Value
Deep value opportunity - significant discount to Professional Services peers
Momentum
Strong
+6.5% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MED right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 27, 2026
MAY 4, 2026
Reported EPS of -$0.19 vs -$0.55 consensus (+65.5% surprise). Revenue of $76.0M vs $69.2M expected (+9.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+65.5%
Next: Apr 27, 2026
Revenue trend · last 8Q
—
—
-38%
-34%
-37%
-36%
-37%
-34%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$168.6M
$140.2M
$119.0M
$115.7M
$105.6M
$89.4M
$75.1M
$76.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
-2.8%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Stephens · $12.00 · Feb 19, 2026